Gil Roth07.18.12
07 CSL
45 Poplar Rd., Parkville
Victoria 3052, Australia
Tel: +61 3 9389 1911
Fax: +61 3 9389 1434
www.csl.com.au
Headcount 10,000
Year Established 1916
Bio/Pharma Revenues $4,145 5%
Total Revenues $4,278 5%
Royalty Revenues $82 -17%
Net Income $931 0%
R&D Budget $322 15%
Top-Selling Drugs
Drug | Indication | $ | (+/- %) |
Immunoglobulins | $1,367 | 30% | |
Plasma-derived coagulants | $478 | 3% | |
Helixate / Recombinant FVIII | $410 | 11% | |
Albumin | $342 | 11% |
Account for 63% of total biopharma sales, up from 56% in previous year.
(Found by getting CSL Behring total sales, broken down into percentages).
NOTE: Fiscal year ends June 30, so these results are based on previous fiscal year, ending June 30, 2011; Australian dollar appreciated 11% from year to year, creating extreme jumps in results in USD